Clinical Trial Update: Study of XL820 Given Orally Daily to Subjects With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of XL820 given orally daily in subjects with solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• XL820

Snippet

Sponsor: Exelixis | Conditions: Cancer | Phase 1 | Status: COMPLETED